MetaCap

Turn Therapeutics (TTRX) vs Vicore Pharma AB (VCRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vicore Pharma AB is the larger company by market cap ($264.9 million vs $247.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TTRX+5.27%VCRE-42.12%
+107%+26%-54%
Jul 6, 20261 yearNov 20, 2026
TTRX-14.25%VCRE-31.75%
+63%+12%-39%
Jul 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TTRX versus VCRE key metrics
MetricTTRXVCRE
Share price$8.10$9.41
Market cap$247.49M$264.89M
1-day change-6.31%-5.09%
YTD return+105.46%—
1-year return+147.55%—
EPS (TTM)$-0.43$-2.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-3.19M—
52-week high$16.45$17.80
52-week low$2.70$7.88
Distance from 52-week high-50.79%-47.16%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+208.83%+158.90%
Average volume119.32K23.31K
Shares outstanding30.57M28.16M
Employees250
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Turn Therapeutics

TTRX stock →

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

About Vicore Pharma AB

VCRE stock →

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees

TTRX vs VCRE FAQ

Which is bigger, Turn Therapeutics or Vicore Pharma AB?

Vicore Pharma AB (VCRE) is larger, with a market capitalization of $264.89M compared with $247.49M for Turn Therapeutics (TTRX).

Are Turn Therapeutics and Vicore Pharma AB in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons